Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

MEDRAD, INC., a business of Bayer HealthCare, has announced the launch of the next generation Intego™ PET Infusion System, which features a new design that is 38% smaller, power-driven and includes enhancements to technologist workflow.

The new Intego will be on display at the Annual Meeting of the Society of Nuclear Medicine (SNM 2011), June 4-8, in San Antonio, Texas.

The Intego PET Infusion System, originally launched in 2008, remains the only FDA-cleared device for automated, controlled infusion of F18-FDG and F18-NaF, the most common PET diagnostic imaging agents used in oncology.  Intego PET Infusion Systems have been sold throughout the world, including the US, Latin America, South America, Europe, Africa, the Middle East, Asia and Australia.

"The new Intego demonstrates our commitment to continued innovation and leadership in molecular imaging.  Now, in an even smaller, more mobile design, Intego can significantly reduce radiation exposure and improve patient care. This is just another way we are driving smarter, safer, simpler PET," says Doug Descalzi, executive director, MEDRAD Molecular Imaging.

Source: MEDRAD, INC.